Literature DB >> 20813217

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.

Steven Black1, Giovanni Della Cioppa, Anne Malfroot, Pantaleo Nacci, Uwe Nicolay, Michele Pellegrini, Etienne Sokal, André Vertruyen.   

Abstract

We reviewed the safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents (aged 6 months-18 years) in an integrated analysis of all pediatric trials evaluating MF59-containing influenza vaccines completed to date (5 trials). In the MF59-adjuvanted group (n=1181) versus the non-adjuvanted group (n=545) there was no increase in the incidence of unsolicited adverse events and serious adverse events. As expected, solicited local or systemic reactions occurred more frequently in MF59-adjuvanted subjects; however, a majority of reactions were mild and transient. These data support the safety of MF59-adjuvanted influenza vaccines in the pediatric population.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20813217     DOI： 10.1016/j.vaccine.2010.08.075

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  10 in total

1.  Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial.

Authors:  Alessandra Viganò; Vania Giacomet; Elena Pariani; Elisa Giani; Valeria Manfredini; Giorgio Bedogni; Paola Erba; Antonella Amendola; Alessandro Zanetti; Gianvincenzo Zuccotti
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

2.  Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.

Authors:  Timo Vesikari; Aino Forstén; Ashwani Arora; Theodore Tsai; Ralf Clemens
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.

Authors:  Iván Bihari; Gyula Pánczél; Jozsef Kovacs; Jenny Beygo; Elena Fragapane
Journal:  Clin Vaccine Immunol       Date:  2012-10-17

4.  Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.

Authors:  Penghui Yang; Yueqiang Duan; Peirui Zhang; Zhiwei Li; Cheng Wang; Mei Dong; Chong Tang; Li Xing; Hongjing Gu; Zhongpeng Zhao; Xiufan Liu; Shaogeng Zhang; Xiliang Wang
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

5.  Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada.

Authors:  David N Fisman; Ashleigh R Tuite
Journal:  PLoS One       Date:  2011-11-14       Impact factor: 3.240

6.  A caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goats.

Authors:  Mariarosaria Marinaro; Giovanni Rezza; Giuseppe Del Giudice; Valeriana Colao; Elvira Tarsitano; Michele Camero; Michele Losurdo; Canio Buonavoglia; Maria Tempesta
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

7.  Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.

Authors:  Mark J Mulligan; David I Bernstein; Sharon Frey; Patricia Winokur; Nadine Rouphael; Michelle Dickey; Srilatha Edupuganti; Paul Spearman; Edwin Anderson; Irene Graham; Diana L Noah; Brian Mangal; Sonnie Kim; Heather Hill; Jenifer Whitaker; William Emery; Allison Beck; Kathy Stephens; Brooke Hartwell; Melinda Ogilvie; Nayoka Rimann; Eileen Osinski; Ellen Destefano; Theda Gajadhar; Amanda Strudwick; Karen Pierce; Lilin Lai; Ling Yue; Dongli Wang; Carl Ying; Amy Cline; Tara Foltz; Nancy Wagner; Geraldine Dull; Thomas Pacatte; Barbara Taggart; Valerie Johnson; Logan Haller; Candi Looney; Shixiong Li; Megan May; Bridgette Myers; Rachel May; Lawanda Parker; Nertaissa Cochran; Donna Bowen; Michelle Bell; Jeffery Scoggins; Angela Burns; Claire Stablein; Mark Wolff; Bernadette Jolles; Brenda Leung; Linda Lambert; Shy Shorer; Wendy Buchanan; Suzanne Murray; Soju Chang; Richard Gorman
Journal:  Open Forum Infect Dis       Date:  2014-11-18       Impact factor: 3.835

Review 8.  AS03- and MF59-Adjuvanted Influenza Vaccines in Children.

Authors:  Amanda L Wilkins; Dmitri Kazmin; Giorgio Napolitani; Elizabeth A Clutterbuck; Bali Pulendran; Claire-Anne Siegrist; Andrew J Pollard
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

Review 9.  Influenza vaccines: Evaluation of the safety profile.

Authors:  Claudia Maria Trombetta; Elena Gianchecchi; Emanuele Montomoli
Journal:  Hum Vaccin Immunother       Date:  2018-01-30       Impact factor: 3.452

10.  Poly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine.

Authors:  Quyen Thi Nguyen; Chaewon Kwak; Wang Sik Lee; Jaemoo Kim; Jinyoung Jeong; Moon Hee Sung; Jihyun Yang; Haryoung Poo
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.